Aetna modified CPB 0671 covering enfuvirtide (Fuzeon) billing under HCPCS code J1324, effective September 26, 2025. Here's what changes for billing teams.
Aetna, a CVS Health company, updated its Enfuvirtide (Fuzeon) coverage policy under CPB 0671 Aetna system. This policy governs reimbursement for J1324 (Injection, enfuvirtide, 1 mg) billed under ICD-10 diagnosis code B20 for HIV disease. If your practice manages HIV treatment patients on Aetna plans, this policy directly affects your prior authorization workflow and claim denial exposure.
Quick-Reference Table
| Field | Detail |
|---|---|
| Payer | Aetna, a CVS Health company |
| Policy | Enfuvirtide (Fuzeon) — CPB 0671 |
| Policy Code | CPB 0671 |
| Change Type | Modified |
| Effective Date | 2025-09-26 |
| Impact Level | Medium |
| Specialties Affected | Infectious Disease, Internal Medicine, HIV/AIDS Specialty Clinics |
| Key Action | Audit active J1324 claims for medical necessity documentation before September 26, 2025 |
Aetna Enfuvirtide Coverage Criteria and Medical Necessity Requirements 2025
The Aetna Enfuvirtide (Fuzeon) coverage policy under CPB 0671 sets two distinct pathways to establish medical necessity for initial approval. Understanding both is critical — one missed documentation element means a denied claim.
Pathway 1 — Treatment failure after adequate therapy: The member must have active viremia despite three or more months of therapy on at least one appropriate HIV regimen. "Appropriate regimen" is the key phrase here. Your clinical documentation needs to show both the duration and the adequacy of prior treatment — not just that the patient tried something else.
Pathway 2 — Resistance or intolerance: The member has active viremia and documented resistance or intolerance to at least one appropriate HIV regimen. Resistance documentation typically means genotypic or phenotypic resistance testing. Intolerance requires clinical notes that show why the prior regimen couldn't continue. If your chart doesn't have that specificity, the prior authorization will fail.
Aetna will not cover enfuvirtide for treatment-naïve patients. That's a hard exclusion. If your team bills J1324 for a patient who hasn't previously failed or been resistant to at least one HIV regimen, expect a claim denial.
For continuation of therapy, Aetna requires documented positive or stable virologic response to enfuvirtide. This means your team needs viral load data in the chart before submitting for continuation authorization. "Stable" matters here — Aetna isn't requiring suppression, just documented response.
Aetna Enfuvirtide Exclusions and Non-Covered Indications
This is where billing teams lose money without knowing it. Aetna explicitly labels two indications as experimental, investigational, or unproven. Claims submitted under these indications will not receive reimbursement.
Treatment-naïve HIV-infected persons. Enfuvirtide is a salvage therapy, not a first-line agent. Aetna's coverage policy reflects that directly. If a patient has never been on antiretroviral therapy, J1324 won't get covered — period. Document prior regimen history before submitting.
Treatment of COVID-19. Aetna calls out U07.1 (COVID-19) as a non-covered indication for enfuvirtide. This is worth noting because researchers explored fusion inhibitors during the pandemic. For billing purposes, any J1324 claim paired with U07.1 as the primary or supporting diagnosis is headed for denial.
Coverage Indications at a Glance
| Indication | Status | Relevant Codes | Notes |
|---|---|---|---|
| HIV-1 infection with viremia after 3+ months on prior regimen | Covered | J1324, B20 | Document duration and adequacy of prior therapy |
| HIV-1 infection with viremia and documented resistance/intolerance | Covered | J1324, B20 | Resistance testing or intolerance documentation required |
| Continuation of therapy with positive/stable virologic response | Covered | J1324, B20 | Viral load data required for continuation authorization |
| Treatment-naïve HIV-infected persons | Not Covered / Experimental | J1324 | No prior regimen history = denied |
| Treatment of COVID-19 | Not Covered / Experimental | J1324, U07.1 | Aetna considers this use unproven |
Aetna Enfuvirtide Billing Guidelines and Action Items 2025
The effective date of September 26, 2025 is your deadline. Here's what your billing team needs to do before then.
| # | Action Item |
|---|---|
| 1 | Audit all active J1324 claims for medical necessity documentation. Pull every active enfuvirtide patient on an Aetna plan. Confirm each chart has documented viremia, prior regimen history (with duration), and either resistance testing results or intolerance documentation. Do this before September 26, 2025. |
| 2 | Update your prior authorization templates for J1324. Make sure your PA request includes the specific prior regimen name, duration of therapy (three or more months for Pathway 1), and lab results supporting active viremia. Vague clinical summaries won't satisfy Aetna's criteria under CPB 0671. |
| 3 | Flag treatment-naïve patients before submission. Build a charge capture check that flags J1324 when there's no documented prior HIV regimen. This stops denial-generating claims before they leave your billing system. |
| 4 | Confirm viral load data is in the chart for continuation requests. Aetna requires a positive or stable virologic response for continuation of therapy. "Stable" is acceptable — but it needs to be documented with actual lab values. A provider note saying "patient doing well" won't hold up on appeal. |
| 5 | Remove U07.1 from any J1324 claim template that includes COVID-19 diagnoses. If your team ever used enfuvirtide under COVID protocols and built any crossover billing templates, clean those out now. J1324 billed with U07.1 is an automatic denial under this coverage policy. |
| 6 | Check your dosing documentation against policy. Aetna's dosage standard is 90 mg twice daily for adults. For pediatric patients (six years and older, weighing at least 11 kg), the dose is 2 mg per kg twice daily up to 90 mg twice daily. If your charted dose doesn't match these parameters, Aetna may question medical necessity. Document weight-based dosing calculations for pediatric patients explicitly. |
| 7 | Talk to your compliance officer if you have any patients who started enfuvirtide under COVID-19 protocols. The overlap between HIV treatment and COVID-19 research use is a gray area with real claim denial and audit risk. Don't guess — loop in your compliance officer before the September 26 effective date. |
| Previous Version | Current Version |
|---|---|
| Coverage is considered experimental and investigational for all indications | Coverage is considered medically necessary when specific criteria are met |
| Prior authorization is not required | Prior authorization is required for initial treatment |
| Documentation must include clinical history | Documentation must include clinical history |
| Re-review every 24 months | Re-review every 12 months with updated clinical documentation |
CPT, HCPCS, and ICD-10 Codes for Enfuvirtide Under CPB 0671
Use the exact codes below. Every J1324 claim needs to pair with B20 to meet Aetna's coverage criteria. U07.1 is listed specifically because it triggers the experimental/not-covered designation.
HCPCS Codes Covered When Selection Criteria Are Met
| Code | Type | Description |
|---|---|---|
| J1324 | HCPCS | Injection, enfuvirtide, 1 mg |
Key ICD-10-CM Diagnosis Codes
| Code | Description | Coverage Status |
|---|---|---|
| B20 | Human immunodeficiency virus [HIV] disease | Covered — when medical necessity criteria are met |
| U07.1 | COVID-19 | Not Covered — Aetna considers enfuvirtide experimental for this indication |
A quick note on J1324 billing units: Enfuvirtide is dosed at 90 mg twice daily for adults. J1324 bills per 1 mg. That's 90 units per dose, 180 units per day. Make sure your charge capture reflects actual administered units — overbilling or underbilling units on J1324 is a common audit trigger on specialty injectables like this one.
Get the Full Picture
Track this policy across versions, search 1,500+ policies by CPT code, and get real-time alerts when any payer changes coverage.